Share Twitter LinkedIn Facebook Email Neelima Denduluri, MD, shares her thoughts on the practice-changing results of the TAILORx study presented at the 2018 Annual Meeting.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read